Uwe Platzbecker

Uwe Platzbecker

UNVERIFIED PROFILE

Are you Uwe Platzbecker?   Register this Author

Register author
Uwe Platzbecker

Uwe Platzbecker

Publications by authors named "Uwe Platzbecker"

Are you Uwe Platzbecker?   Register this Author

100Publications

3511Reads

22Profile Views

Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design.

J Clin Oncol 2020 Feb 14:JCO1901823. Epub 2020 Feb 14.

German Cancer Consortium (DKTK), partner site Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01823DOI Listing
February 2020

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.

Ann Hematol 2020 Jan 25;99(1):7-19. Epub 2019 Oct 25.

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03799-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944671PMC
January 2020

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

N Engl J Med 2020 01;382(2):140-151

From Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire (CHU) de Lille, Lille (B.Q.), the Department of Internal Medicine, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse (O.B.-R.), and Université Cote d'Azur, Département d'Hématologie Clinique, CHU Nice, Nice (T.C.) - all in France; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig (U.P.), Klinik für Hämatologie, Onkologie, and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf (U.G.), and Klinik und Poliklinik für Innere Medizin III, Technische Universität München, Munich (K.S.G.) - all in Germany; the Department of Haemato-Oncology, King's College London, London (G.J.M.), Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford (P.V.), and the Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds (D.B.) - all in the United Kingdom; the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.G.-M.); Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (R.B.); MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence (V.S.), the Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna (C.F.), the University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia (M.C.), the Hematology Unit, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria (F.S., V.G.), and Dipartimento Biomedicina e Prevenzione, University of Rome Tor Vergata, Rome (M.-T.V.) - all in Italy; the Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca (M.D.-C.), Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville (J.F.F.), and the Department of Hematology, Hospital Universitario Cruces, Vizcaya (B.A.) - all in Spain; the Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey (O.I.); the Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland (M.A.S.); the Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges (D.S.), and Universitair Ziekenhuis Gent, Ghent (D.M.) - both in Belgium; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (A.E.D.); the Division of Hematology-Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (J.G.J.), and Albert Einstein College of Medicine (A.V.) - both in New York; the Department of Hematology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands (E.V.); Stanford University Cancer Center, Stanford, CA (P.L.G.); the Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm (E.H.-L.); the Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT (A.M.Z.); Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville (M.R.S.); Celgene, Summit, NJ (A.L., J.Z., A.R., D.R.D.); Celgene International, Boudry, Switzerland (A.B.); Acceleron Pharma, Cambridge, MA (P.G.L., M.L.S.); and Moffitt Cancer Center, Tampa, FL (R.S.K., A.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908892DOI Listing
January 2020

Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.

Curr Treat Options Oncol 2020 Jan 30;21(1). Epub 2020 Jan 30.

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Liebigstrasse 22, Haus 7, 04103, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0695-5DOI Listing
January 2020

Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing.

Antimicrob Agents Chemother 2019 Dec 20;64(1). Epub 2019 Dec 20.

Department for Gastroenterology, Section of Hepatology, University Hospital Leipzig AöR, Leipzig, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.01525-19DOI Listing
December 2019

Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study.

JAMA Oncol 2019 Dec 12. Epub 2019 Dec 12.

Medical Department-Hematology and Cell Therapy, Medical Oncology, Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.5135DOI Listing
December 2019

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Blood Adv 2019 Nov;3(21):3449-3453

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018022434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855118PMC
November 2019

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia.

Cancers (Basel) 2019 Oct 23;11(11). Epub 2019 Oct 23.

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, 04103 Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11111625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893483PMC
October 2019

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Ann Hematol 2019 Sep 16;98(9):2063-2072. Epub 2019 Jul 16.

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Liebigstraße 22, 04103, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03756-1DOI Listing
September 2019

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.

J Clin Med 2019 Sep 25;8(10). Epub 2019 Sep 25.

National Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8101534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832659PMC
September 2019

How we manage adults with myelodysplastic syndrome.

Br J Haematol 2019 Sep 30. Epub 2019 Sep 30.

service d'hématologie séniors, hôpital St Louis, assistance publique - hôpitaux de Paris (APHP) and Université de Paris, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16206DOI Listing
September 2019

Tracking myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides.

Haematologica 2019 Aug 31;104(8):e349-e351. Epub 2019 Jan 31.

Helmholtz-Institute for Biomedical Engineering, Stem Cell Biology and Cellular Engineering, RWTH Aachen University, Aachen

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.209734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669165PMC
August 2019

The wolf of hypomethylating agent failure: what comes next?

Haematologica 2019 08;104(8):1505-1508

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Germany.

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2019.222794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669157PMC
August 2019

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes.

Int J Mol Sci 2019 Aug 7;20(16). Epub 2019 Aug 7.

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, 04103 Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20163853DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720617PMC
August 2019

Treatment of MDS.

Authors:
Uwe Platzbecker

Blood 2019 03 22;133(10):1096-1107. Epub 2019 Jan 22.

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany; German MDS Study Group, Leipzig, Germany; and European Myelodysplastic Syndromes Cooperative Group, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-10
Publisher Site
http://dx.doi.org/10.1182/blood-2018-10-844696DOI Listing
March 2019

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Blood 2019 02 2;133(8):790-794. Epub 2019 Jan 2.

Medical Clinic and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-876888DOI Listing
February 2019

Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Drugs 2018 Dec;78(18):1873-1885

Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, 04103, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40265-018-1011-6
Publisher Site
http://dx.doi.org/10.1007/s40265-018-1011-6DOI Listing
December 2018

Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 09 21;24(9):1947-1951. Epub 2018 May 21.

Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany; Deutsche Knochenmarkspenderdatei Clinical Trials Unit, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.05.021DOI Listing
September 2018

Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data.

Leuk Res 2018 06 21;69:81-86. Epub 2018 Apr 21.

TU Dresden, Medizinische Fakultät Carl Gustav Carus, Center for Evidence-Based Healthcare, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.04.010DOI Listing
June 2018

Management of patients with acute promyelocytic leukemia.

Leukemia 2018 06 24;32(6):1277-1294. Epub 2018 Apr 24.

Medical Clinic I, University Hospital Carl-Gustav-Carus, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0139-4DOI Listing
June 2018

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.

Lancet Haematol 2018 May 5;5(5):e201-e210. Epub 2018 Apr 5.

Medizinische Fakultät Carl-Gustav-Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, University Hospital Carl-Gustav-Carus, Dresden, Germany; National Center for Tumor Diseases (NCT)-Partner Site Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30036-XDOI Listing
May 2018

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Cancers (Basel) 2018 May 24;10(6). Epub 2018 May 24.

Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10060158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025349PMC
May 2018

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.

Clin Lymphoma Myeloma Leuk 2018 02 30;18(2):136-144.e7. Epub 2017 Dec 30.

Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.12.004DOI Listing
February 2018

Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications.

Curr Pharm Des 2016 ;22(16):2323-32

Department of Medicine I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612822666160226132914DOI Listing
November 2017

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

Eur J Haematol 2017 Aug 20;99(2):112-118. Epub 2017 Apr 20.

Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.12883
Publisher Site
http://dx.doi.org/10.1111/ejh.12883DOI Listing
August 2017

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

J Clin Oncol 2017 Jul 2;35(19):2157-2164. Epub 2017 May 2.

Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg; Georg-Nikolaus Franke, University Hospital Leipzig, Leipzig; Uwe Platzbecker, University Hospital Dresden, Dresden; Kai Hübel and Christof Scheid, University of Cologne, Cologne; Thomas Weber, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle; Matthias Stelljes, University of Münster, Münster; Peter Dreger, University of Heidelberg, Heidelberg; Andreas Günther, University Hospital Schleswig Holstein Campus Kiel, Kiel; Wolfgang Bethge, University Hospital Tübingen, Tübingen; Guido Kobbe, Heinrich Heine University, Düsseldorf, Germany; Simona Iacobelli, Università Tor Vergata, Rome; Giorgio Lambertenghi Deliliers and Francesco Onida, Fondazione IRCC Ca' Granda Ospedale Maggiore Policlinico, University of Milano, Milan; Massimo Pini, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria; Stefano Guidi, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; Ruzena Uddin, Guy's Hospital, London, United Kingdom; Marie Robin, Hôpital Saint Louis, Assistance Publique Hôpitaux Paris, France; Boris Afanasyev, SPB Pavlov Medical University, St Petersburg, Russia; Dominik Heim, University Hospital Basel, Basel Switzerland; Liisa Volin, Helsinki University Hospital, Helsiniki, Finland; Xavier Poiré, Cliniques Universitaires St-Luc, Brussels, Belgium; Marleen van Os, European Group of Blood and Marrow Transplantation Clinical Trials Office; Ronald Brand, Leiden University Medical Center, Leiden; and Theo de Witte, Radboud University Medical Center, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7349DOI Listing
July 2017

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.

Semin Hematol 2017 07 4;54(3):141-146. Epub 2017 Jul 4.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany, German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2017.06.004DOI Listing
July 2017

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Leuk Lymphoma 2017 05 23;58(5):1271-1272. Epub 2016 Sep 23.

a Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav-Carus, Technische Universität , Dresden , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1225209DOI Listing
May 2017

From occasional date to civil union in APL.

Authors:
Uwe Platzbecker

Blood 2017 03;129(10):1235

UNIVERSITY HOSPITAL CARL GUSTAV CARUS DRESDEN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-759761DOI Listing
March 2017

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

J Clin Oncol 2017 Feb 31;35(6):605-612. Epub 2016 Oct 31.

Uwe Platzbecker, Christian Thiede, Christoph Röllig, and Gerhard Ehninger, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden; Uwe Platzbecker and Gerhard Ehninger, Study Alliance Leukemia, Dresden; Walter Fiedler, University Hospital Hamburg-Eppendorf; Norbert Schmitz, Asklepios Klinik St Georg Hamburg, Hamburg; Peter Brossart, Innere Medizin mit deSchwerpunkten Onkologie, Haematollogie un Rheumatologie, Bonn; Bernd Hertenstein, Klinikum Bremen Mitte, Bremen; Helmut R. Salih, University Hospital Tubingen; Mohammed Wattad, Kliniken Essen Süd, Essen; Michael Lübbert, University Medical Center, Freiburg; Christian H. Brandts, Goethe University Frankfurt, Frankfurt; Mathias Hänel, Klinikum Chemnitz gGmbH, Chemnitz; Hartmut Link, Klinik für Innere Medizin I, Westpfalz-Klinikum, Kaiserslautern; Konstanze Döhner, Hartmut Döhner, and Richard F. Schlenk, University Hospital Ulm, Ulm; Arnold Ganser, Hannover Medical School, Hannover, Germany; Giuseppe Avvisati, University Campus Bio-Medico; Laura Cicconi, Mariadomenica Divona, Sergio Amadori, and Francesco Lo-Coco, University Tor Vergata; Francesca Paoloni, Marco Vignetti, Fabio Efficace, Paola Fazi, and Franco Mandelli, Gruppo Italiano Malattie Ematologiche dell'Adulto Central Office; Marco Vignetti and Massimo Breccia, Sapienza University, Rome; Felicetto Ferrara, Cardarelli Hospital, Naples; Francesco Albano, University of Bari, Bari; Marco Sborgia, U.O. di Ematologia Clinica, Pescara; Eros Di Bona, San Bortolo Hospital, Vicenza; Erika Borlenghi, U.O. di Ematologia, Spedali Civili, Brescia; Roberto Cairoli, Ospedale Niguarda, Ca' Granda, SC Ematologia; Agostino Cortelezzi, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milano; Alessandro Rambaldi, Azienda Opsedaliera Papa Giovanni XXIII, Bergamo; Lorella Melillo, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo; Giorgio La Nasa, Centro Trapianti Midollo Osseo, Ospedale R. Binaghi, Università di Cagliari, Cagliari; Chiara Frairia, Hematology, Città della Salute e della Scienza, Torino; Enrico Maria Pogliani, Ospedale San Gerardo, Università degli Studi Milano Bicocca, Monza; Claudio Fozza, University of Sassari, Sassari; Alfonso Maria D'Arco, U.O. Medicina Interna e Onco-Ematologica P.O. "Umberto I," Nocera Inferiore, Nocera Inferiore; Nicola Di Renzo, Ospedale Vito Fazzi, Lecce; and Francesco Fabbiano, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1982DOI Listing
February 2017

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).

Leuk Res 2017 Jan 13;52:50-57. Epub 2016 Nov 13.

AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.11.008DOI Listing
January 2017

Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.

Haematologica 2016 12 18;101(12):1499-1507. Epub 2016 Aug 18.

Department of Medicine III, Technische Universität Dresden, Saxony, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.144808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479606PMC
December 2016

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.

Curr Hematol Malig Rep 2016 12;11(6):416-424

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-016-0347-9DOI Listing
December 2016

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Ann Hematol 2016 Oct 10;95(11):1805-10. Epub 2016 Aug 10.

Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität, Fetscherstr, 74, 01307, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2775-yDOI Listing
October 2016

Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells.

J Bone Miner Res 2016 10 13;31(10):1877-1887. Epub 2016 May 13.

Department of Clinical Pathobiochemistry, Technische Universität Dresden, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.2857DOI Listing
October 2016

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

J Clin Oncol 2016 09 27;34(25):2988-96. Epub 2016 Jun 27.

Valeria Santini, University of Florence, Florence, Italy; Antonio Almeida, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal; Aristoteles Giagounidis and Stefanie Gröpper, Marien Hospital Düsseldorf; Norbert Gattermann, Heinrich-Heine-Universität, Düsseldorf; Uwe Platzbecker, Technical University Dresden, Dresden, Germany; Anna Jonasova, Charles University General Hospital, Prague, Czech Republic; Norbert Vey, Centre Régional de Lutte Contre le Cancer, Marseille; Pierre Fenaux, Université Paris, Paris, France; Francis Séguy and Albert Hoenekopp, Celgene International, Boudry, Switzerland; Ghulam J. Mufti, King's College Hospital, London, United Kingdom; Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Moshe Mittelman and Ron Ram, Tel Aviv University; Ofer Shpilberg, Assuta Medical Center, Tel Aviv, Israel; Consuelo del Cañizo, Hospital Universitario de Salamanca, Salamanca; Alberto Risueño, Celgene Institute for Translational Research Europe, Seville, Spain; Keiya Ozawa, The University of Tokyo, Tokyo, Japan; Kyle J. MacBeth, Celgene Corporation, San Francisco, CA; and Jianhua Zhong and C.L. Beach, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.0118DOI Listing
September 2016

Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study.

Leuk Res 2016 08 27;47:128-35. Epub 2016 May 27.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.05.022DOI Listing
August 2016

Recent frustration and innovation in myelodysplastic syndrome.

Haematologica 2016 08;101(8):891-3

Service d'Hématologie Seniors, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris et Université Paris 7, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.142836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967566PMC
August 2016

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Medicine (Baltimore) 2016 May;95(20):e3355

From the Department of Internal Medicine I (GJ, HLM, PM, JC, LJ, SC, TJ); Department of Medical Clinic III, University of Bonn, Bonn (VM, HA, BP, WD); Department of Hematology, Oncology, Hemostaseology, and SCT, Faculty of Medicine, University Hospital of the RWTH Aachen University, Aachen (KA, BTH, KS); Department of Biometrics, Informatics and Epidemiology, University of Bonn, Bonn (FR); Department for Hematology, University Hospital Essen, Essen (GJ); Department for Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf (GN); Practice for Hematology-Oncology Eppendorf, Hamburg (GE); and Department for Hematology, University Hospital Dresden, Dresden, Germany (PU).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000003355DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902387PMC
May 2016